22 April 2025 - AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for the prostate cancer indication.

Korea Biomedical Review has learned that AstraZeneca Korea submitted a reimbursement application for Lynparza to  HIRA on April 18. The company has applied for insurance coverage for both indications, which are supported by two phase 3 clinical trials: the PROfound and PROpel studies.

Read Korea Biomedical Review article